Late life depression is highly prevalent and associated with an increased risk of morbidity, poor physical and cognitive functioning, and suicide. Yet, standard antidepressants are often ineffective; thus, many older adults have treatment-resistant depression (TRD, defined as failure of two oral antidepressants). Few medication options exist for TRD in older adults, with aripiprazole being one notable exception.
1Electroconvulsive therapy is often the next step in treatment but is limited in availability and often associated with short-term memory loss.
- Hsu JH
- Mulsant BH
- Lenze EJ
- et al.
Impact of prior treatment on remission of late-life depression with venlafaxine and subsequent aripiprazole or placebo augmentation.
Am J Geriatr Psychiatry. 2016; 24: 918-922https://doi.org/10.1016/j.jagp.2016.04.015
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to The American Journal of Geriatric Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Impact of prior treatment on remission of late-life depression with venlafaxine and subsequent aripiprazole or placebo augmentation.Am J Geriatr Psychiatry. 2016; 24: 918-922https://doi.org/10.1016/j.jagp.2016.04.015
- The efficacy and safety of esketamine for the treatment-resistant depression in older adults: comments on TRANSFORM-3 trial results.Am J Geriatr Psychiatry. 2020; 28: 142-144https://doi.org/10.1016/j.jagp.2019.10.009
- Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report.Am J Psychiatry. 2006; 163: 1905-1917https://doi.org/10.1176/ajp.2006.163.11.1905
- Continuation electroconvulsive therapy vs pharmacotherapy for relapse prevention in major depression: a multisite study from the Consortium for Research in Electroconvulsive Therapy (CORE).Arch Gen Psychiatry. 2006; 63: 1337-1344https://doi.org/10.1001/archpsyc.63.12.1337
- Failed response to repeat intravenous ketamine infusions in geriatric patients with major depressive disorder.J Clin Psychopharmacol. 2014; 34: 285-286https://doi.org/10.1097/JCP.0000000000000090
- Intraoperative ketamine for prevention of depressive symptoms after major surgery in older adults: an international, multicentre, double-blind, randomised clinical trial.Br J Anaesth. 2018; 121: 1075-1083https://doi.org/10.1016/j.bja.2018.03.030
- Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression-TRANSFORM-3.Am J Geriatr Psychiatry. 2020; 28: 121-141https://doi.org/10.1016/j.jagp.2019.10.008
- Pilot randomized controlled trial of titrated subcutaneous ketamine in older patients with treatment-resistant depression.Am J Geriatr Psychiatry. 2017; 25: 1199-1209https://doi.org/10.1016/j.jagp.2017.06.007
Published online: January 18, 2021
Accepted: January 12, 2021
Received: January 9, 2021
© 2021 American Association for Geriatric Psychiatry. Published by Elsevier Inc. All rights reserved.